Home Epigenetics Sirtuin activator Salvianolic acid B

Salvianolic acid B

Catalog No.S4735 Synonyms: Sal B, Lithospermate B, Lithospermic acid B

For research use only.

Salvianolic acid B (Sal B, Lithospermate B, Lithospermic acid B), an antioxidant and free radical scavenging compound, is the most abundant bioactive compound extracted from the root of Salvia miltiorrhiza Bunge.

Salvianolic acid B Chemical Structure

CAS No. 121521-90-2

Selleck's Salvianolic acid B has been cited by 2 Publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Related Compound Libraries

Other Sirtuin Products

Download Inhibitor Catalog

Download Inhibitor Catalog
Sirtuin Signaling Pathways

Sirtuin Signaling Pathway Map

Biological Activity

Description Salvianolic acid B (Sal B, Lithospermate B, Lithospermic acid B), an antioxidant and free radical scavenging compound, is the most abundant bioactive compound extracted from the root of Salvia miltiorrhiza Bunge.
Targets
SIRT [2]
()
In vitro

Salvianolic acid B, also known as satanic acid B or lithospermic acid B, is a new generation of the natural antioxidants. It can influence Ca2+ aggregation and endothelial cell NO release of hypoxia/ reoxygenation-induced cell. When acid B concentration is 2.5, 5, and 10 mg/l, cell viability and superoxide dismutase (SOD) activity are enhanced, and the formation of malondialdehyde (MDA) in human umbilical vein endothelial cells (ECV304) is inhibited. SalB inhibits HG-induced oxidative stress and reduces the generation of ROS and 8-hydroxy-2-deoxyguanosine (8-OHDG) and mitochondrial depolarization and apoptosis in a dose-dependent manner. It can downregulate the expression of Bax and AIF nuclear translocation and cytochrome c release mediated by HG, but upregulate the expression of Bcl-2 induced by HG. Besides, SalB attenuates HG-induced caspase of the enzyme 3, 9 and minimize PARP cleavage of Schwann cells (SCs). SalB inhibits angiotensin II or H2O2 and TNF-α-induced gelatinolytic activity in human aortic smooth muscle cells (HASMCs) in a concentration-dependent manner. Salvianolic acid B can inhibit platelet aggregation and adhesion. Salvianolic acid B can promote cardiac angiogenesis effect. SalB can enhance cell activity and reduce the number of sub-G1 and apoptotic nuclei of ischemic cell model in order to show its antiapoptotic effects. Salvianolic acid B inhibits ischemia and hypoxia of myocardial injury. Salvianolic acid B inhibits the synthesis of type I collagen of non-TGF-1 stimulated human hepatic stellate cell line (LX-2)[1]. SalB activates mammalian sirtuins 1 (SIRT1), an NAD-dependent class III histone deacetylase (HDAC) that plays important roles in several physiological processes, including gene transcription, senescence, energy metabolism, oxidative stress and inflammation[2]. (HG：High glucose)
In vivo Salvianolic acid B can significantly reduce the myocardial infarct size and blood lactate dehydrogenase level of model rat with acute myocardial infarction, improve cardiac function and myocardial tissue structure, thus inhibiting ischemia and hypoxia of myocardial injury. salvianolic acid B can improve blood hemorheology, reduce oxidative damage, improve the vascular endothelial cell function, and prevent the development of coronary artery disease. Salvianolic acid B could selectively inhibit the activity of MMP-9 in a rat model of myocardial infarction. Salvianolic acid B can also effectively increase the thickness of the left ventricular wall in the myocardial infarction rats to improve the contraction of the heart, and reduce cardiac fibrosis[1]. SalB treatment ameliorates ethanol-induced hepatic inflammation by decreasing the levels of hepatotoxic cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). SalB has beneficial effects against hepatic fibrosis in animal models and has been shown to possess cardioprotective and neuroprotective activity via anti-oxidative and anti-inflammatory actions[2].

Protocol (from reference)

Cell Research:

[2]
  • Cell lines: The HepG2 human hepatoma cell line
  • Concentrations: 8 μM
  • Incubation Time: 3 h
  • Method:

    The HepG2 human hepatoma cell line is cultured in MEM containing 10% (v/v) FBS. The cells are incubated at 37℃ in humidified air with 5% CO2. HepG2 cells are seeded at a density of 1×105 cells per well and grown for 24 h. After this, the cells are treated with 8 μM SalB for 3 h or 10 mM Ex527 or RES for 6 h. Then, the cells are exposed to 100 mM ethanol for 48 h.

  • (Only for Reference)
Animal Research:

[2]
  • Animal Models: Male Sprague-Dawley rats
  • Dosages: 15 or 30 mg/kg/d
  • Administration: intragastric administration
  • (Only for Reference)

Solubility (25°C)

In vitro

 DMSO 100 mg/mL
(139.15 mM)
Water 100 mg/mL
(139.15 mM)
Ethanol 100 mg/mL
(139.15 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 718.61
Formula

C36H30O16
CAS No. 121521-90-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C=C1CC(C(=O)O)OC(=O)C=CC2=C3C(C(OC3=C(C=C2)O)C4=CC(=C(C=C4)O)O)C(=O)OC(CC5=CC(=C(C=C5)O)O)C(=O)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02694848 Unknown status Drug: Salvianolate injection|Drug: Aspirin Angina China Academy of Chinese Medical Sciences|Xiyuan Hospital of China Academy of Chinese Medical Sciences|Guang''anmen Hospital of China Academy of Chinese Medical Sciences|General Hospital of Beijing PLA Military Region|Guangdong Provincial Hospital of Traditional Chinese Medicine February 2016 Phase 4

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Salvianolic acid B | Salvianolic acid B supplier | purchase Salvianolic acid B | Salvianolic acid B cost | Salvianolic acid B manufacturer | order Salvianolic acid B | Salvianolic acid B distributor